10% ROE, 1% ROA from 6.67% ROE& 0.75 %ROA in previous quarter. With increasing operating leverage and slowing down treasury losses ROA&ROE will further increase. Asset quality improving. NPA ratios and absolute numbers improved sequentially. With a retail focused book with Presently PB ratio of 1.1, this is a rerating candidate for sure and a no brainer buy!!!
Disclosure: Invested. Recent transactions in 48 hours.
I don’t think Krsnaa is an opt comparison. Sharda’s business model is that of a pure marketeer, who outsources manufacturing and spends money on registration of its products and on marketing. If you want a peer from a different industry, cos like Chaman Lal Setia (basmati rice), Symphony (coolers) or Dash Pharma (US generic pharma) come to mind, where manufacturing is outsourced and company is only responsible for marketing.
Yes, a company needs to register its products to sell in regulated markets (EU, NAFTA, LATAM). The difference in other cos is they only register a few products (which they manufacture in their factories) in multiple geographies. Whereas, Sharda registers multiple products in multiple geographies, as they are not manufacturing them and don’t have to spend money in building dedicated lines for any product. In a way, Sharda’s business model is akin to a trader, where the entry barrier is distributor relationship and registration.
In its early days, Ajanta Pharma also used to do this, i.e. register products which are in demand in a given market and then get it manufactured with a third party.
Hope this is of some help.
Thanks for clear information
M&M is on a sweet ride.
Mahindra Scorpio-N clocks 1 lakh bookings in under 30 minutes | Team-BHP
A lot of buyers are still sitting on the fence as they fear a price rise.
Mahindra XUV700 Amasses 1.5 Lakh Bookings Despite Lengthy Waiting Periods | CarDekho.com
Mahindra XUV400 EV spied in production-spec guise: exterior design and more | Autocar India
Both cars cost 20,00,000 Rupees. The factories will be running at capacity for the next 12 months or more.
As per previous plans, Micro Power was to be increased from 250 TPM to 375 TPM. Not sure, if the same has been changed in recent times.
Here is some info from Q4’22:
Prices for PFA/FEP/ LiPF6 for the quarter stood at US$25/25/70 per kg respectively.
Something from my notes (must be from one of the research reports, need to look for source 
):
We understand GFL’s recently-commissioned R142b capacity can potentially service ~1000 tonnes per month of PVDF output at peak (~10x from current levels of ~100 tonnes per month output).
Thanks,
Tarun
Idfc bank q1fy23 results:
Slowly slowly 10% RoE 15% RoE can also come. Only the patience can reap the rewards since Rome & banks are not built in a day.
Disclaimer: invested, biased.
Results out. 119 crore jump in PPOP.
To make 18%, we must have stocks that will grow at 20%. Kotak, Hdfc Bank might have done it in the past, cannot generalize it or take it for granted.
And to figure out which ones will, is something we can know only posthumously. As in, surely, bluechips won’t grow 18%, so we find other large or mid caps.
And, out of fifty such investors say 10 might get the right mix of businesses to achieve 18% but others won’t. So, it’s not an excat science. It’s iffy.
That’s what I meant.
I didn’t mean, it cannot be done. I meant, it cannot be done consistently.
It says three product applications so looks like they have filed one more ANDA by now. We will know in the upcoming concall.
After selling havells means?